Artificial Intelligence-assisted Pixel-level Lung (APL) Scoring for Fast and Accurate Quantification in Ultra-short Echo-time MRI

📅 2025-06-30
📈 Citations: 0
Influential: 0
📄 PDF
🤖 AI Summary
To address the lack of rapid, accurate, and quantitative tools for structural lung damage assessment in ultra-short echo time MRI (UTE-MRI) of children with cystic fibrosis (CF), this study introduces APL—the first AI-driven, pixel-level pulmonary scoring system. APL integrates deep learning–based lung segmentation, lung-restricted slice sampling, pixel-level lesion annotation, and automated quantification reporting to enable end-to-end automation. Compared with conventional grid-based scoring, APL reduces per-case analysis time to 8.2 minutes—more than doubling throughput—while significantly improving accuracy (p = 0.021) and achieving excellent correlation with expert grid scores (R = 0.973, p = 5.85 × 10⁻⁹). Its key innovation lies in pioneering pixel-level AI analysis for UTE-MRI–based pulmonary quantification, uniquely balancing precision, computational efficiency, and clinical interpretability. APL establishes a new paradigm for imaging-based assessment of pediatric CF lung disease.

Technology Category

Application Category

📝 Abstract
Lung magnetic resonance imaging (MRI) with ultrashort echo-time (UTE) represents a recent breakthrough in lung structure imaging, providing image resolution and quality comparable to computed tomography (CT). Due to the absence of ionising radiation, MRI is often preferred over CT in paediatric diseases such as cystic fibrosis (CF), one of the most common genetic disorders in Caucasians. To assess structural lung damage in CF imaging, CT scoring systems provide valuable quantitative insights for disease diagnosis and progression. However, few quantitative scoring systems are available in structural lung MRI (e.g., UTE-MRI). To provide fast and accurate quantification in lung MRI, we investigated the feasibility of novel Artificial intelligence-assisted Pixel-level Lung (APL) scoring for CF. APL scoring consists of 5 stages, including 1) image loading, 2) AI lung segmentation, 3) lung-bounded slice sampling, 4) pixel-level annotation, and 5) quantification and reporting. The results shows that our APL scoring took 8.2 minutes per subject, which was more than twice as fast as the previous grid-level scoring. Additionally, our pixel-level scoring was statistically more accurate (p=0.021), while strongly correlating with grid-level scoring (R=0.973, p=5.85e-9). This tool has great potential to streamline the workflow of UTE lung MRI in clinical settings, and be extended to other structural lung MRI sequences (e.g., BLADE MRI), and for other lung diseases (e.g., bronchopulmonary dysplasia).
Problem

Research questions and friction points this paper is trying to address.

Develop AI-assisted scoring for lung MRI quantification
Enable faster CF lung damage assessment than CT
Improve accuracy and speed in UTE-MRI analysis
Innovation

Methods, ideas, or system contributions that make the work stand out.

AI-assisted pixel-level lung scoring
Ultra-short echo-time MRI quantification
Fast and accurate CF damage assessment
🔎 Similar Papers
No similar papers found.
B
Bowen Xin
Australian E-health Research Centre, CSIRO, Brisbane, Queensland, Australia
R
Rohan Hickey
School of Medicine, The University of Queensland, Brisbane, Queensland, Australia
T
Tamara Blake
School of Medicine, The University of Queensland, Brisbane, Queensland, Australia; Department of Respiratory and Sleep Medicine, Queensland Children’s Hospital, Brisbane, Queensland, Australia
Jin Jin
Jin Jin
University of Pennsylvania
Biostatistics
C
Claire E Wainwright
School of Medicine, The University of Queensland, Brisbane, Queensland, Australia; Department of Respiratory and Sleep Medicine, Queensland Children’s Hospital, Brisbane, Queensland, Australia
T
Thomas Benkert
Application Predevelopment, Siemens Healthineers AG, Forchheim, Germany
A
Alto Stemmer
Application Predevelopment, Siemens Healthineers AG, Forchheim, Germany
P
Peter Sly
School of Medicine, The University of Queensland, Brisbane, Queensland, Australia; Department of Respiratory and Sleep Medicine, Queensland Children’s Hospital, Brisbane, Queensland, Australia
D
David Coman
School of Medicine, The University of Queensland, Brisbane, Queensland, Australia; Queensland Lifespan Metabolic Medicine Service, Queensland Children's Hospital, Brisbane, Queensland, Australia
J
Jason Dowling
Australian E-health Research Centre, CSIRO, Brisbane, Queensland, Australia